To ask the Secretary of State for Health, if his Department will provide an evaluation of the clinical differences between the quadrivalent and bivalent vaccines available for use in the HPV vaccination programme.
23 March 2016
The clinical characteristics and efficacy of the quadrivalent and bivalent human papillomavirus (HPV) vaccines have been evaluated in clinical trials, reported in scientific publications and to vaccine regulators.
Estimates of the potential impact of the HPV vaccination programme on cancer and warts have been previously published by Public Health England (PHE). The quadrivalent vaccine is expected to prevent up to 95% of vaccine related anogenital warts a year in males and females.
PHE has previously published data and analyses showing a reduction in genital warts in England associated with bivalent vaccination:
A decrease in genital warts was not anticipated for the bivalent vaccine. However, rates of genital warts have declined significantly amongst the population vaccinated as reported in genito-urinary medicine (GUM) clinics. Data reported to PHE from GUM clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014 of 30.6% in 15-19 year-old females and 25.4% amongst same age heterosexual males.